Clay Thorp, Director, 10% Owner at PhaseBio Pharmaceuticals Inc (PHAS), bought 4,000 shares at $3.13 ($13K) on 2018-12-04, disclosed to the SEC on 2018-12-06.
Open-market purchase of $13k PHAS by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CLSD | BUY | 2022-12-21 | $14K | — | Filing → |
| VIGL | BUY | 2022-05-17 | $165K | — | Filing → |
| VIGL | BUY | 2022-03-28 | $22K | — | Filing → |